Senior onderzoeker Huisartsgeneeskundige Zorg; projectleider Nivel Surveillance - Nivel Zorgregistraties Eerste Lijn
Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019.
Kissling, E., Rose, A., Emborg, H.D., Gherasim, A., Pebody, R., Pozo, F., Trebbien, R., Mazagatos, C., Whitaker, H., Valenciano, M., European IVE Group, Donker, G.A., Hooiveld, M. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. Eurosurveillance: 2019, 24(8)Read online
Influenza A(H1N1)pdm09 and A(H3N2) viruses both circulated in Europe in October 2018–January 2019. Interim results from six studies indicate that 2018/19 influenza vaccine effectiveness (VE) estimates among all ages in primary care was 32–43% against influenza A; higher against A(H1N1)pdm09 and lower against A(H3N2). Among hospitalised older adults, VE estimates were 34–38% against influenza A and slightly lower against A(H1N1)pdm09. Influenza vaccination is of continued benefit during the ongoing 2018/19 influenza season.